Study Stopped
Change in excimer laser systems prior to completion of study
A Comparison of Photorefractive Keratectomy (PRK), PRK With Mitomycin-C and Laser Subepithelial Keratomileusis (LASEK) in the Treatment of Moderate and High Myopia
A Prospective Comparison of Photorefractive Keratectomy (PRK), PRK With Mitomycin-C and Laser Subepithelial Keratomileusis (LASEK) in the Treatment of Moderate and High Myopia
1 other identifier
interventional
960
1 country
1
Brief Summary
The purpose of this study is to assess whether there is a significant difference in visual outcomes or corneal haze after surface ablation for moderate and high myopia in active duty service members treated with PRK, Mitomycin-C (MMC) PRK and LASEK.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2004
CompletedFirst Submitted
Initial submission to the registry
December 21, 2006
CompletedFirst Posted
Study publicly available on registry
December 22, 2006
CompletedJuly 16, 2010
July 1, 2010
December 21, 2006
July 15, 2010
Conditions
Outcome Measures
Primary Outcomes (1)
Efficacy in terms of uncorrected visual acuity and post operative refraction. Safety in terms of maintenance of best spectacle corrected acuity within 2 lines of preoperative levels.
12 months after surgery
Study Arms (3)
2
ACTIVE COMPARATORLASEK- laser-assisted subepithelial keratectomy
3
ACTIVE COMPARATORMitomycin C PRK
1
ACTIVE COMPARATORPRK- Photorefractive keratectomy
Interventions
Eligibility Criteria
You may qualify if:
- Informed consent.
- Normal, healthy, active duty adults age 21 years or older. The lower age limit of 21 years is intended to ensure documentation of refractive stability.
- Manifest refractive spherical equivalent of greater than -4.00 diopters (D) up to -10.00 D.
- Best spectacle corrected visual acuity of 20/20 or better in both eyes.
- Demonstrated refractive stability, confirmed by clinical records. Neither the spherical nor the cylindrical portion of the refraction may have changed more than 0.50D during the 12-month period immediately preceding the baseline examination, as confirmed by clinical records.
- Both eyes must fall in the same refraction group and there must be less than 1 D difference between eyes.
- Soft contact lens users must have removed their lenses at least 2 weeks before baseline measurements. Hard contact lens users (PMMA or rigid gas permeable lenses) must have removed their lenses at least 4 weeks prior to baseline measurements and have 2 central keratometry readings and 2 manifest refractions taken at least 1 week apart that do not differ by more than 0.50 D in either meridian.
- Access to transportation to meet the follow-up requirements.
- Available for evaluation during the 1-year follow-up period.
- Consent of the subject's command to participate in the study.
You may not qualify if:
- Female subjects who are pregnant, breast-feeding or intend to become pregnant during the study. Women of childbearing age will take a urine pregnancy test before starting this study.
- Residual, recurrent or active ocular diseases or corneal abnormalities in either eye such as keratoconus, iritis, uveitis, keratoconjunctivitis sicca, vernal conjunctivitis, lagophthalmos, corneal scarring, glaucoma, previous steroid responder, occludable chamber angles, visually significant cataracts.
- Medical condition(s), which, in the judgment of the investigator, may impair healing, including but not limited to: collagen vascular disease, autoimmune disease, immunodeficiency diseases, and ocular herpes zoster or simplex.
- Concurrent topical or systemic medications that may impair healing, including corticosteroids, antimetabolites, isotretinoin (Accutane), amiodarone hydrochloride (Cordarone) and/or sumatripin (Imitrex).
- Any physical or mental impairment that would preclude participation in any of the examinations.
- Prior refractive or ocular surgery.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Walter Reed Army Medical Centerlead
- Madigan Army Medical Centercollaborator
- C.R.Darnall Army Medical Centercollaborator
- Blanchfield Army Community Hospitalcollaborator
- Tripler Army Medical Centercollaborator
Study Sites (1)
Walter Reed Army Medical Center, Center For Refractive Surgery
Washington D.C., District of Columbia, 20307, United States
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
KRAIG S BOWER, MD
DIRECTOR, CENTER FOR REFRACTIVE SURGERY WALTER REED ARMY MEDICAL CENTER
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- FED
Study Record Dates
First Submitted
December 21, 2006
First Posted
December 22, 2006
Study Start
June 1, 2004
Last Updated
July 16, 2010
Record last verified: 2010-07